The post Blue Jays ‘Interested’ In Stealing Rival Closer After $210 Million Move: Insiders appeared on BitcoinEthereumNews.com. TORONTO, ON – APRIL 14: Ross Atkins, general manager of the Toronto Blue Jays, speaks during a press conference before Vladimir Guerrero Jr. signs a 14-year contract extension at Rogers Centre on April 14, 2025 in Toronto, Ontario, Canada. (Photo by Mark Blinch/Getty Images) Getty Images The Toronto Blue Jays came excruciatingly close to winning it all in the World Series and things might have gone better had their bullpen been a little more dependable. The Blue Jays struggled throughout the season to close out games and their best late-inning option, Jeff Hoffman, blew a save in Game 7 of the World Series to hand the Los Angeles Dodgers the victory. Now the team is looking to obtain a new high-leverage arm or two to ensure that doesn’t happen again next season. After the team added free agent starter Dylan Cease with a $210 million contract, the Blue Jays have reportedly been involved in pursuits of several notable relief pitchers. “The Jays, who are in agreement with free-agent right-hander Dylan Cease on a seven-year contract, continue to pursue late-inning relievers, and were in the mix for three who already signed — (Ryan) Helsley, Raisel Iglesias and Phil Maton,” Major League Baseball insiders Ken Rosenthal and Katie Woo reported for The Athletic. Though the Jays lost out on those options — with Helsley reportedly agreeing to a $28 million contract from the American League East division rival Baltimore Orioles — they are now pursuing another rival’s former closer, per Rosenthal and Woo. “With Ryan Helsley off the market, Pete Fairbanks might be the next closer to sign,” they added. “The Toronto Blue Jays and Miami Marlins are among the teams interested in him, according to industry sources briefed on his market.” Fairbanks posted a 2.83 ERA with 59 strikeouts across more… The post Blue Jays ‘Interested’ In Stealing Rival Closer After $210 Million Move: Insiders appeared on BitcoinEthereumNews.com. TORONTO, ON – APRIL 14: Ross Atkins, general manager of the Toronto Blue Jays, speaks during a press conference before Vladimir Guerrero Jr. signs a 14-year contract extension at Rogers Centre on April 14, 2025 in Toronto, Ontario, Canada. (Photo by Mark Blinch/Getty Images) Getty Images The Toronto Blue Jays came excruciatingly close to winning it all in the World Series and things might have gone better had their bullpen been a little more dependable. The Blue Jays struggled throughout the season to close out games and their best late-inning option, Jeff Hoffman, blew a save in Game 7 of the World Series to hand the Los Angeles Dodgers the victory. Now the team is looking to obtain a new high-leverage arm or two to ensure that doesn’t happen again next season. After the team added free agent starter Dylan Cease with a $210 million contract, the Blue Jays have reportedly been involved in pursuits of several notable relief pitchers. “The Jays, who are in agreement with free-agent right-hander Dylan Cease on a seven-year contract, continue to pursue late-inning relievers, and were in the mix for three who already signed — (Ryan) Helsley, Raisel Iglesias and Phil Maton,” Major League Baseball insiders Ken Rosenthal and Katie Woo reported for The Athletic. Though the Jays lost out on those options — with Helsley reportedly agreeing to a $28 million contract from the American League East division rival Baltimore Orioles — they are now pursuing another rival’s former closer, per Rosenthal and Woo. “With Ryan Helsley off the market, Pete Fairbanks might be the next closer to sign,” they added. “The Toronto Blue Jays and Miami Marlins are among the teams interested in him, according to industry sources briefed on his market.” Fairbanks posted a 2.83 ERA with 59 strikeouts across more…

Blue Jays ‘Interested’ In Stealing Rival Closer After $210 Million Move: Insiders

TORONTO, ON – APRIL 14: Ross Atkins, general manager of the Toronto Blue Jays, speaks during a press conference before Vladimir Guerrero Jr. signs a 14-year contract extension at Rogers Centre on April 14, 2025 in Toronto, Ontario, Canada. (Photo by Mark Blinch/Getty Images)

Getty Images

The Toronto Blue Jays came excruciatingly close to winning it all in the World Series and things might have gone better had their bullpen been a little more dependable.

The Blue Jays struggled throughout the season to close out games and their best late-inning option, Jeff Hoffman, blew a save in Game 7 of the World Series to hand the Los Angeles Dodgers the victory. Now the team is looking to obtain a new high-leverage arm or two to ensure that doesn’t happen again next season.

After the team added free agent starter Dylan Cease with a $210 million contract, the Blue Jays have reportedly been involved in pursuits of several notable relief pitchers.

“The Jays, who are in agreement with free-agent right-hander Dylan Cease on a seven-year contract, continue to pursue late-inning relievers, and were in the mix for three who already signed — (Ryan) Helsley, Raisel Iglesias and Phil Maton,” Major League Baseball insiders Ken Rosenthal and Katie Woo reported for The Athletic.

Though the Jays lost out on those options — with Helsley reportedly agreeing to a $28 million contract from the American League East division rival Baltimore Orioles — they are now pursuing another rival’s former closer, per Rosenthal and Woo.

“With Ryan Helsley off the market, Pete Fairbanks might be the next closer to sign,” they added. “The Toronto Blue Jays and Miami Marlins are among the teams interested in him, according to industry sources briefed on his market.”

Fairbanks posted a 2.83 ERA with 59 strikeouts across more than 60 innings for the Tampa Bay Rays in this past season and he has performed particularly well against the Blue Jays in recent divisional matchups. In 27 career innings against the Blue Jays, Fairbanks has held their hitters to a dismal .130 batting average.

So, while there are some more standout closer options still on the market, including Edwin Diaz, Devin Williams and Robert Suarez, Fairbanks could be an enticing option for the Blue Jays. It seems likely they will be addressing the bullpen in short order, especially after their decision to bring Cease in to fortify the rotation.

“The Blue Jays have Jeff Hoffman in the closer’s role for now and Louis Varland in place as a high-powered setup man, but the Seranthony Dominguez role needs to be replaced,” Keegan Matheson wrote for MLB.com. “The Blue Jays adding an established closer is absolutely possible, especially after this bold, decisive first step into free agency.”

Source: https://www.forbes.com/sites/peterchawaga/2025/12/01/blue-jays-interested-in-stealing-rival-closer-after-210-million-move-insiders/

Market Opportunity
Bluefin Logo
Bluefin Price(BLUE)
$0,03486
$0,03486$0,03486
-0,65%
USD
Bluefin (BLUE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26